Pre-market Hot Trades in US Stocks
Nuwellis, up 12.63% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Decent, up 11.33% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Top Gainers in Pre-market US Stocks
INVO Fertility, up 413.29% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Icon Energy, up 120.10% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
RAPT, up 63.53% in pre-market. Based on recent key news:
<ol>
<li>
On January 20, GSK announced the acquisition of RAPT Therapeutics for $2.2 billion, driving RAPT's pre-market stock price up 65%. This acquisition will give GSK global rights to RAPT's experimental food allergy drug ozureprubart, excluding mainland China, Macau, Taiwan, and Hong Kong. This move expands GSK's respiratory, immunology, and inflammation product lines. Source: Reuters
</li>
<li>
On January 20, GSK plans to acquire RAPT at a price of $58 per share, representing a significant premium over RAPT's last closing price. This transaction is expected to be completed in the first quarter, with GSK assuming milestone and royalty payment responsibilities to RAPT's partner, Shanghai Jieyou Pharmaceutical. Source: MT Newswires
</li>
<li>
On January 20, GSK's Chief Scientific Officer Tony Wood stated that ozureprubart is expected to be a best-in-class treatment option, providing sustained protection every 12 weeks, aligning with GSK's strategy to acquire assets that address clear unmet medical needs. Source: Dow Jones Newswires. The biotech industry is experiencing active merger and acquisition activities, with significant capital inflows
</li>
</ol>

NUWE

DXST

Nuwellis pre-market up 12.63%; Decent pre-market up 11.33%; INVO Fertility pre-market up 413.29%; Icon Energy pre-market up 120.10%; RAPT Therapeutics pre-market up 63.53%

Pre-market hot trades in US stocks: Nuwellis up 12.63% in pre-market; Decent up 11.33% in pre-market